| P50 | author | Alzheimer's Disease Neuroimaging Initiative | Q4738819 |
| | John Q. Trojanowski | Q6253636 |
| | Leslie M. Shaw | Q106957202 |
| | Christos Davatzikos | Q29348045 |
| | Clifford Jack | Q30505709 |
| | Jon B. Toledo | Q37386709 |
| | Michael W. Weiner | Q56850515 |
| | Kewei Chen | Q56850573 |
| | Eric M. Reiman | Q56863017 |
| | Steven E. Arnold | Q64157128 |
| | Maria Bjerke | Q97016106 |
| P2093 | author name string | Martin Rozycki | |
| P2860 | cites work | Use of Florbetapir-PET for Imaging β-Amyloid Pathology | Q22253015 |
| | Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q24595802 |
| | The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception | Q27006831 |
| | Mild cognitive impairment: clinical characterization and outcome | Q28140626 |
| | Longitudinal imaging pattern analysis (SPARE-CD index) detects early structural and functional changes before cognitive decline in healthy older adults | Q28260610 |
| | The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q29547554 |
| | Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers | Q29620245 |
| | Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI) | Q30552776 |
| | Relationship between plasma analytes and SPARE-AD defined brain atrophy patterns in ADNI | Q31110973 |
| | Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition | Q33559175 |
| | Highly accurate inverse consistent registration: a robust approach | Q34160493 |
| | An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease | Q34364368 |
| | The preclinical Alzheimer cognitive composite: measuring amyloid-related decline | Q34422469 |
| | Characterizing Alzheimer's disease using a hypometabolic convergence index | Q34733606 |
| | Mild cognitive impairment: ten years later | Q34847370 |
| | Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. | Q34940642 |
| | Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. | Q35218413 |
| | Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI | Q35821382 |
| | Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease | Q35948528 |
| | Within-subject template estimation for unbiased longitudinal image analysis | Q36075413 |
| | CSF biomarkers cutoffs: the importance of coincident neuropathological diseases | Q36551527 |
| | Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias | Q36623399 |
| | An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease | Q36650399 |
| | A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment | Q36933757 |
| | Optimally-Discriminative Voxel-Based Morphometry significantly increases the ability to detect group differences in schizophrenia, mild cognitive impairment, and Alzheimer's disease | Q37025490 |
| | Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later | Q37035638 |
| | Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid | Q37107044 |
| | Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects | Q37227424 |
| | Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre | Q37380546 |
| | Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers | Q37410700 |
| | Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study | Q37524511 |
| | Correlating cerebral hypometabolism with future memory decline in subsequent converters to amnestic pre-mild cognitive impairment | Q40049601 |
| | Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease | Q41140682 |
| | COMPARE: classification of morphological patterns using adaptive regional elements. | Q45965571 |
| | CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study | Q48381623 |
| | Classification of non-demented patients attending a memory clinic using the new diagnostic criteria for Alzheimer's disease with disease-related biomarkers | Q48609740 |
| | Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment. | Q51899594 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biomarker | Q864574 |
| | cognitive dysfunction | Q57859955 |
| P304 | page(s) | 144-153 | |
| P577 | publication date | 2015-06-17 | |
| P1433 | published in | Neurology | Q1161692 |
| P1476 | title | Memory, executive, and multidomain subtle cognitive impairment: clinical and biomarker findings | |
| P478 | volume | 85 | |